Tailored tetravalent antibodies potently and specifically activate wnt/frizzled pathways in cells, organoids and mice
eLife, ISSN: 2050-084X, Vol: 8
2019
- 75Citations
- 92Captures
- 20Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations75
- Citation Indexes69
- 69
- CrossRef53
- Patent Family Citations6
- Patent Families6
- Captures92
- Readers92
- 92
- Mentions20
- News Mentions20
- News20
Most Recent News
AntlerA antibody drug for treatment of vascular retinopathies
SAN FRANCISCO , June 9, 2021 /PRNewswire/ -- AntlerA has applied its next generation programmable ANT platform to develop therapeutics for treating retinopathies. Blood vessels
Article Description
Secreted Wnt proteins regulate development and adult tissue homeostasis by binding and activating cell-surface Frizzled receptors and co-receptors including LRP5/6. The hydrophobicity of Wnt proteins has complicated their purification and limited their use in basic research and as therapeutics. We describe modular tetravalent antibodies that can recruit Frizzled and LRP5/6 in a manner that phenocopies the activities of Wnts both in vitro and in vivo. The modular nature of these synthetic Frizzled and LRP5/6 Agonists, called FLAgs, enables tailored engineering of specificity for one, two or multiple members of the Frizzled family. We show that FLAgs underlie differentiation of pluripotent stem cells, sustain organoid growth, and activate stem cells in vivo. Activation of Wnt signaling circuits with tailored FLAgs will enable precise delineation of functional outcomes directed by distinct receptor combinations and could provide a new class of therapeutics to unlockthe promise of regenerative medicine.
Bibliographic Details
10.7554/elife.46134; 10.7554/elife.46134.006; 10.7554/elife.46134.018; 10.7554/elife.46134.012; 10.7554/elife.46134.001; 10.7554/elife.46134.002
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85071617462&origin=inward; http://dx.doi.org/10.7554/elife.46134; http://www.ncbi.nlm.nih.gov/pubmed/31452509; https://elifesciences.org/articles/46134; https://elifesciences.org/articles/46134#fig2; http://dx.doi.org/10.7554/elife.46134.006; https://elifesciences.org/articles/46134#fig4; http://dx.doi.org/10.7554/elife.46134.018; https://elifesciences.org/articles/46134#fig3; http://dx.doi.org/10.7554/elife.46134.012; https://elifesciences.org/articles/46134#abstract; http://dx.doi.org/10.7554/elife.46134.001; https://elifesciences.org/articles/46134#fig1; http://dx.doi.org/10.7554/elife.46134.002; https://dx.doi.org/10.7554/elife.46134
eLife Sciences Publications, Ltd
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know